Blog
RSS FeedPosted by Michael Wonder on 31 Jan 2019
Relief as government funded hep C drugs become available
1 February 2019 - The "modern lepers" of the health system have come in from exile, hepatitis C campaigner Hazel ...
Posted by Michael Wonder on 31 Jan 2019
Decision to open access to atomoxetine and change funded brand
31 January 2019 - PHARMAC is pleased to announce that all funding restrictions on atomoxetine will be removed from 1 ...
Posted by Michael Wonder on 31 Jan 2019
New Zealand Pharmaceutical Schedule - 1 February 2019 update
1 February 2019 - The February 2019 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 29 Jan 2019
Ibrance: tough pill to swallow for two Rotorua women fighting for lives
26 January 2019 - One Rotorua woman has had to sell her rental property to pay the thousands of dollars ...
Posted by Michael Wonder on 22 Jan 2019
Northland dad with brain tumour needs $60k to fund drug to extend his life
22 January 2019 - A Northland father-of-four with an aggressive brain tumour is desperate to see his daughters grow up ...
Posted by Michael Wonder on 22 Jan 2019
PHARMAC publishes PTAC outcome for nivolumab in renal cell carcinoma
22 January 2019 - The Committee reviewed the application for nivolumab for the second-line treatment of relapsed clear cell renal ...
Posted by Michael Wonder on 22 Jan 2019
PTAC recommends Keytruda for patients with non-small cell lung cancer
22 January 2019 - PTAC reviewed an application from Merck Sharpe and Dohme for the funding of pembrolizumab in combination ...
Posted by Michael Wonder on 21 Jan 2019
Contraceptive pill Levlen ED rationed as supply runs low across New Zealand
21 January 2019 - Popular contraceptive pill Levlen ED is being rationed amidst fears of a shortage. ...
Posted by Michael Wonder on 20 Jan 2019
Tauranga women fighting cancer, and fighting the system
19 January 2019 - Two Tauranga woman, each living with a terminal diagnosis, are calling for an independent inquiry into ...
Posted by Michael Wonder on 11 Jan 2019
Notification of decision involving treatments for multiple sclerosis, narcolepsy, and attention deficit hyperactivity disorder
11 January 2019 - PHARMAC is pleased to announce the approval of a multi-product agreement with Teva Pharma New Zealand ...
Posted by Michael Wonder on 10 Jan 2019
Decision to list a new presentation of raltegravir and amend arrangements for raltegravir and posaconazole
10 January 2019 - PHARMAC is pleased to announce its decision to approve a multi-product agreement with Merck Sharpe & ...
Posted by Michael Wonder on 04 Jan 2019
Kaitaia woman's life and death choice as PHARMAC says no to funding drug
28 December 2018 - Kaitaia mum Donna MacMillan is a glass-half-full kind of person despite being terminally ill with advanced ...
Posted by Michael Wonder on 02 Jan 2019
New Zealand Pharmaceutical Schedule - 1 January 2019 update
1 January 2019 - The January 2019 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 20 Dec 2018
Breast cancer drug lobbyists let down by PHARMAC's response to funding
20 December 2018 - Breast cancer sufferers have been dealt a blow in their mission to have life-extending drugs funded ...
Posted by Michael Wonder on 20 Dec 2018
Decisions relating to the funded brands of some anti-retroviral treatments for HIV
20 December 2018 - PHARMAC is pleased to announce decisions to award sole supply for seven anti-retroviral treatments used in ...